Friday 6-6-2014 Bristol-Myers Squibb Company (BMY) $BMY opened at 47.40 hitting the high price of 47.49 and a day low of 46.89 with a total volume of 7,643,300. BMY had a previous close of 47.21 and has been seeing an average volume of 9,365,155.
Overall Average: 96% Sell
Recent stock forum discussions about BMY http://investorshangout.com/search?q=BMY&...mp;yt0=Go!
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Jun 06, 7:09PM CDT
Next week Cramer will be watching for positive data out of China and company earnings in the U.S. (full story)
Final Glance: Pharmaceuticals companies
AP - Fri Jun 06, 5:13PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading: (full story)
3 Pharma Giants Battling for Immuno-Oncology Dominance
Eric Thomasson, The Motley Fool - Motley Fool - Fri Jun 06, 5:00PM CDT
Cancer drugs have been taking center stage in recent months. Some of the drugs making the biggest headlines come from the field of immuno-oncology, which are drugs that manipulate the body's immune system in an effort to fight cancer. Three... (full story)
Midday Glance: Pharmaceuticals companies
AP - Fri Jun 06, 12:22PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.: (full story)
Early Glance: Pharmaceuticals companies
AP - Fri Jun 06, 10:46AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.: (full story)
5 Toxic Big Pharma Stocks You Need to Sell This Summer
at The Street - Fri Jun 06, 10:33AM CDT
As the summer fast approaches, pharma and medical device stocks are starting to show some nasty side effects. (full story)
Is Bristol-Myers Squibb's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Fri Jun 06, 8:30AM CDT
Bristol-Myers Squibb is one of the globe's top drugmakers and a staple in dividend investors' portfolios. Big drug companies such as Bristol-Myers, Johnson & Johnson , and Merck offer investors predictable, dividend-boosting revenue... (full story)
MediPoint: Companion Diagnostic Tests in Oncology - Current and Future Players
M2 - Fri Jun 06, 4:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mfmskz/medipoint) has announced the addition of the "MediPoint: Companion Diagnostic Tests in Oncology - Current and Future Players" report to their offering. A companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows the safe application of a therapy. In-vitro Companion Diagnostic tests measure the expression or presence of a specific biomarker that is linked to a disease condition or therapy. This report provides an analysis of the companion diagnostic market for four major cancers in the US, the 5EU (France, Germany, Italy, Spain, and UK), Brazil, and the some of the Asia-Pacific (APAC) regions (Japan, China, and India), and identifies the unmet needs in this companion diagnostics market. This report analyses companion diagnostic tests used in breast, colorectal, melanoma and non-small cell lung cancer. This report also discusses physician attitudes towards current companion diagnostic tests, and the future of companion diagnostic tests. This report focuses on the major test kits that are supplied to pathology laboratories. The report identifies and analyzes the key companies shaping and driving the Companion Diagnostic market. The report provides insight into the competitive Companion Diagnostic landscape, including new companies entering the market and pipeline products in development. Scope - Investigation of current and future market competition for Companion Diagnostic - Competitor assessment including device approval analysis. - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of the device sector through market impact analysis, future market scenario and company analysis. - Direct quotes from Key Opinion Leaders (KOL) as well as doctors using Companion Diagnostic in clinical practice. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Competitive Assessment - Techniques in Use by Currently Marketed Products - Immunohistochemistry - Fluorescence In Situ Hybridization - Polymerase Chain Reaction - Breast Cancer Companion Diagnostic Tests - Colorectal Cancer Companion Diagnostic Tests - Melanoma Companion Diagnostic Tests - Non-Small Cell Lung Cancer Companion Diagnostic Tests 4 Pipeline Products - Breast Cancer Companion Diagnostic Tests - Colorectal Cancer Companion Diagnostic Tests - Melanoma Companion Diagnostic Tests - Non-Small Cell Lung Cancer Companion Diagnostic Tests 5 Current and Future Players - Trends in Corporate Strategy - Companion Diagnostics Business Models - Company Profiles - Pharmaceutical/Therapy Companies Developing Companion Diagnostic Tests - Diagnostics Companies Developing Companion Diagnostic Tests (in Partnership with Pharmaceutical Companies) 6 Appendix Companies Mentioned - Amgen - Arno Therapeutics - AstraZeneca - Bristol-Myers Squibb - Clovis Oncology - Eli Lilly and Company - Genentech (Roche) - Pfizer - Syndax Pharmaceuticals - Abbott Laboratories - Amoy Diagnostics (Amoy Diagnostics) - Biogenex Laboratories - BioM?rieux - Dako (Agilent Technologies) - Illumina - Leica Biosystems - Life Technologies (Thermo Fisher Scientific) - MolecularMD - Myriad Genetics - Qiagen - Roche Diagnostics - Siemens Healthcare - Ventana Medical Systems For more information visit http://www.researchandmarkets.com/research/mfmskz/medipoint (full story)
Most active New York Stock Exchange-traded stocks
AP - Thu Jun 05, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading: (full story)
Bristol-Myers Focuses on India - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 4:47PM CDT
In a bid to expand its footprint in India,Bristol-Myers (BMY) extended its tie-up with Syngene International by five years. (full story)
NYSE stocks posting largest percentage decreases
AP - Thu Jun 05, 12:22PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on New York Stock Exchange at 1 p.m.: (full story)
Thought Leader Opinion Indicates That There is Significant Commercial Opportunity in Developing Therapies that Can Improve Overall Survival in First-Line Advanced Ovarian Cancer
PR Newswire - Thu Jun 05, 12:00PM CDT
Decision Resources Group finds that in addition to an improvement in median overall survival (MOS), delayed disease progression is one of the greatest unmet needs in the first-line treatment of advanced ovarian cancer (CaO). MOS and disease progression are also key factors that shape surveyed U.S. and European oncologists' treatment decisions in this patient population. According to interviewed experts and survey data, substantial commercial opportunity exists for therapies that would improve MOS in first-line advanced CaO. Based on early-phase clinical data and the opinions of thought leaders interviewed the emerging therapies profiled by Decision Resources Group are not expected to offer significant improvements in overall survival, safety and tolerability, or delivery over currently used therapies. However, interviewed thought leaders anticipate that at least two emerging therapies; AstraZeneca's PARP inhibitor olaparib and Boehringer Ingelheim's angiogenesis inhibitor Vargatef will considerably prolong progression-free survival (PFS) in the first-line advanced CaO patients. The anticipated improvements in PFS offered by olaparib and Vargatef over the 2013 sales-leading regimen in this patient population, paclitaxel (Bristol-Myers Squibb's Taxol, generics) + carboplatin (Bristol-Myers Squibb's Paraplatin, generics), match the surveyed U.S. payers' PFS requirements for widespread inclusion on their managed care organizations' formularies. (full story)
Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany
M2 - Thu Jun 05, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4jll46/glioblastoma) has announced the addition of the "Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany" report to their offering. During the 2012-2019 forecast period, the GBM market is expected to grow rapidly from $305m to $583m. Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the Glioblastoma Multiforme (GBM) market. In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck's Temodar (temozolomide), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche's Avastin (bevacizumab), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment. The market entry of Northwest Biotherapeutics' DCVax-L, a dendritic cell-based therapeutic vaccine that acts as an add-on to the standard treatment in newly diagnosed patients, will account for much of this growth. Having demonstrated superior OS improvement compared with the standard treatment alone in clinical trials, it is expected to bear high market potential, given that its efficacy is translated into larger Phase III trials. The cancer vaccine Rindopepimut (CDX-110) and targeted therapy Cotara will also enter the GBM market, but will drive growth to a lesser extent. However, unmet needs are likely to remain in the relapsed setting over the forecast period due to the lack of superior OS benefits in the late-stage pipeline. Scope - A brief introduction to GBM, including the disease pathogenesis, risk factors and diagnosis - In-depth analysis of the drugs available for the treatment of GBM, including safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy - A comprehensive review of the developmental pipeline for GBM, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period, with the pipeline analyzed by Phase distribution, molecule type and molecular target - Additional in-depth analysis of GBM clinical trials by Phase, molecule type, trial size, trial duration and program failure rate - Multi-scenario forecast data for the GBM market to 2019, taking into account the introduction of new drugs, the expiry of key patents and the changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain - Discussion of the drivers of and barriers to market growth - Discussion of the licensing and co-development deals landscape in GBM Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed drugs - Temodar (temozolomide) - Merck - Avastin (bevacizumab) - Roche - BiCNU (carmustine) and Gliadel Wafer (carmustine in polifeprosan) - BiCNU (carmustine) - Bristol-Myers Squibb - Gliadel Wafer (carmustine in polifeprosan) - Eisai - Lomustine - Carboplatin - Cyclophosphamide - Etoposide - Irinotecan 4 Glioblastoma Pipeline - DCVax-L - Northwest Biotherapeutics - Rindopepimut (CDX-110) - Celldex Therapeutics - Avastin (bevacizumab)- Roche - ICT-107 - ImmunoCellular Therapeutics - Cotara- Peregrine Pharmaceuticals - Eir-060- EirGen Pharma - Heat Map of Safety and Efficacy and Competitor Matrix for Glioblastoma Multiforme Pipeline 5 Market forecasts 6 Deals and Strategic Consolidations - Del Mar Pharmaceuticals Enters into Agreement with Guangxi Wuzhou Pharmaceutical - Immatics Biotechnologies Enters into Agreement with Cancer Research UK - ImmunoCellular Therapeutics Enters into Agreement with University of Pennsylvania - Bexion Pharmaceuticals Enters into Agreement with Cincinnati Children's Hospital Medical Center - Celldex Therapeutics Enters into Agreement with Duke University Brain Tumor Cancer Center 7 Appendix For more information visit http://www.researchandmarkets.com/research/4j...ioblastoma (full story)
Why Diamond Offshore Drilling Inc., Bristol-Meyers Squibb Company, and Allergan Inc. Are Today's 3 W
John Divine, The Motley Fool - Motley Fool - Wed Jun 04, 8:02PM CDT
It was a relatively unremarkable day on Wall Street today, a low-volume session that lacked astounding economic data or headline-making broad market swings. But beneath the stock market's calm surface, there was a healthy dose of chaos brewing -- a... (full story)
ASCO: Bristol-Myers Squibb and Merck Don't Disappoint
Brian Orelli, The Motley Fool - Motley Fool - Wed Jun 04, 6:38PM CDT
We knew going into American Society of Clinical Oncology annual meeting that immuno-oncology would be a big focus. And Bristol-Myers Squibb and Merck didn't disappoint. Rather than attacking the tumor directly, immuno-oncology drugs encourage... (full story)
Is Merck's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jun 04, 5:00PM CDT
Merck is one of the world's biggest drugmakers and is a staple in dividend investors' portfolios. That's because pharmaceutical companies such as Merck, Johnson & Johnson , and Bristol-Myers Squibb offer investors a steady (and... (full story)
Overall Average: 96% Sell
Recent stock forum discussions about BMY http://investorshangout.com/search?q=BMY&...mp;yt0=Go!
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Jun 06, 7:09PM CDT
Next week Cramer will be watching for positive data out of China and company earnings in the U.S. (full story)
Final Glance: Pharmaceuticals companies
AP - Fri Jun 06, 5:13PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading: (full story)
3 Pharma Giants Battling for Immuno-Oncology Dominance
Eric Thomasson, The Motley Fool - Motley Fool - Fri Jun 06, 5:00PM CDT
Cancer drugs have been taking center stage in recent months. Some of the drugs making the biggest headlines come from the field of immuno-oncology, which are drugs that manipulate the body's immune system in an effort to fight cancer. Three... (full story)
Midday Glance: Pharmaceuticals companies
AP - Fri Jun 06, 12:22PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.: (full story)
Early Glance: Pharmaceuticals companies
AP - Fri Jun 06, 10:46AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.: (full story)
5 Toxic Big Pharma Stocks You Need to Sell This Summer
at The Street - Fri Jun 06, 10:33AM CDT
As the summer fast approaches, pharma and medical device stocks are starting to show some nasty side effects. (full story)
Is Bristol-Myers Squibb's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Fri Jun 06, 8:30AM CDT
Bristol-Myers Squibb is one of the globe's top drugmakers and a staple in dividend investors' portfolios. Big drug companies such as Bristol-Myers, Johnson & Johnson , and Merck offer investors predictable, dividend-boosting revenue... (full story)
MediPoint: Companion Diagnostic Tests in Oncology - Current and Future Players
M2 - Fri Jun 06, 4:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mfmskz/medipoint) has announced the addition of the "MediPoint: Companion Diagnostic Tests in Oncology - Current and Future Players" report to their offering. A companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows the safe application of a therapy. In-vitro Companion Diagnostic tests measure the expression or presence of a specific biomarker that is linked to a disease condition or therapy. This report provides an analysis of the companion diagnostic market for four major cancers in the US, the 5EU (France, Germany, Italy, Spain, and UK), Brazil, and the some of the Asia-Pacific (APAC) regions (Japan, China, and India), and identifies the unmet needs in this companion diagnostics market. This report analyses companion diagnostic tests used in breast, colorectal, melanoma and non-small cell lung cancer. This report also discusses physician attitudes towards current companion diagnostic tests, and the future of companion diagnostic tests. This report focuses on the major test kits that are supplied to pathology laboratories. The report identifies and analyzes the key companies shaping and driving the Companion Diagnostic market. The report provides insight into the competitive Companion Diagnostic landscape, including new companies entering the market and pipeline products in development. Scope - Investigation of current and future market competition for Companion Diagnostic - Competitor assessment including device approval analysis. - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of the device sector through market impact analysis, future market scenario and company analysis. - Direct quotes from Key Opinion Leaders (KOL) as well as doctors using Companion Diagnostic in clinical practice. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Competitive Assessment - Techniques in Use by Currently Marketed Products - Immunohistochemistry - Fluorescence In Situ Hybridization - Polymerase Chain Reaction - Breast Cancer Companion Diagnostic Tests - Colorectal Cancer Companion Diagnostic Tests - Melanoma Companion Diagnostic Tests - Non-Small Cell Lung Cancer Companion Diagnostic Tests 4 Pipeline Products - Breast Cancer Companion Diagnostic Tests - Colorectal Cancer Companion Diagnostic Tests - Melanoma Companion Diagnostic Tests - Non-Small Cell Lung Cancer Companion Diagnostic Tests 5 Current and Future Players - Trends in Corporate Strategy - Companion Diagnostics Business Models - Company Profiles - Pharmaceutical/Therapy Companies Developing Companion Diagnostic Tests - Diagnostics Companies Developing Companion Diagnostic Tests (in Partnership with Pharmaceutical Companies) 6 Appendix Companies Mentioned - Amgen - Arno Therapeutics - AstraZeneca - Bristol-Myers Squibb - Clovis Oncology - Eli Lilly and Company - Genentech (Roche) - Pfizer - Syndax Pharmaceuticals - Abbott Laboratories - Amoy Diagnostics (Amoy Diagnostics) - Biogenex Laboratories - BioM?rieux - Dako (Agilent Technologies) - Illumina - Leica Biosystems - Life Technologies (Thermo Fisher Scientific) - MolecularMD - Myriad Genetics - Qiagen - Roche Diagnostics - Siemens Healthcare - Ventana Medical Systems For more information visit http://www.researchandmarkets.com/research/mfmskz/medipoint (full story)
Most active New York Stock Exchange-traded stocks
AP - Thu Jun 05, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading: (full story)
Bristol-Myers Focuses on India - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 4:47PM CDT
In a bid to expand its footprint in India,Bristol-Myers (BMY) extended its tie-up with Syngene International by five years. (full story)
NYSE stocks posting largest percentage decreases
AP - Thu Jun 05, 12:22PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on New York Stock Exchange at 1 p.m.: (full story)
Thought Leader Opinion Indicates That There is Significant Commercial Opportunity in Developing Therapies that Can Improve Overall Survival in First-Line Advanced Ovarian Cancer
PR Newswire - Thu Jun 05, 12:00PM CDT
Decision Resources Group finds that in addition to an improvement in median overall survival (MOS), delayed disease progression is one of the greatest unmet needs in the first-line treatment of advanced ovarian cancer (CaO). MOS and disease progression are also key factors that shape surveyed U.S. and European oncologists' treatment decisions in this patient population. According to interviewed experts and survey data, substantial commercial opportunity exists for therapies that would improve MOS in first-line advanced CaO. Based on early-phase clinical data and the opinions of thought leaders interviewed the emerging therapies profiled by Decision Resources Group are not expected to offer significant improvements in overall survival, safety and tolerability, or delivery over currently used therapies. However, interviewed thought leaders anticipate that at least two emerging therapies; AstraZeneca's PARP inhibitor olaparib and Boehringer Ingelheim's angiogenesis inhibitor Vargatef will considerably prolong progression-free survival (PFS) in the first-line advanced CaO patients. The anticipated improvements in PFS offered by olaparib and Vargatef over the 2013 sales-leading regimen in this patient population, paclitaxel (Bristol-Myers Squibb's Taxol, generics) + carboplatin (Bristol-Myers Squibb's Paraplatin, generics), match the surveyed U.S. payers' PFS requirements for widespread inclusion on their managed care organizations' formularies. (full story)
Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany
M2 - Thu Jun 05, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4jll46/glioblastoma) has announced the addition of the "Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany" report to their offering. During the 2012-2019 forecast period, the GBM market is expected to grow rapidly from $305m to $583m. Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the Glioblastoma Multiforme (GBM) market. In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck's Temodar (temozolomide), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche's Avastin (bevacizumab), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment. The market entry of Northwest Biotherapeutics' DCVax-L, a dendritic cell-based therapeutic vaccine that acts as an add-on to the standard treatment in newly diagnosed patients, will account for much of this growth. Having demonstrated superior OS improvement compared with the standard treatment alone in clinical trials, it is expected to bear high market potential, given that its efficacy is translated into larger Phase III trials. The cancer vaccine Rindopepimut (CDX-110) and targeted therapy Cotara will also enter the GBM market, but will drive growth to a lesser extent. However, unmet needs are likely to remain in the relapsed setting over the forecast period due to the lack of superior OS benefits in the late-stage pipeline. Scope - A brief introduction to GBM, including the disease pathogenesis, risk factors and diagnosis - In-depth analysis of the drugs available for the treatment of GBM, including safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy - A comprehensive review of the developmental pipeline for GBM, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period, with the pipeline analyzed by Phase distribution, molecule type and molecular target - Additional in-depth analysis of GBM clinical trials by Phase, molecule type, trial size, trial duration and program failure rate - Multi-scenario forecast data for the GBM market to 2019, taking into account the introduction of new drugs, the expiry of key patents and the changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain - Discussion of the drivers of and barriers to market growth - Discussion of the licensing and co-development deals landscape in GBM Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed drugs - Temodar (temozolomide) - Merck - Avastin (bevacizumab) - Roche - BiCNU (carmustine) and Gliadel Wafer (carmustine in polifeprosan) - BiCNU (carmustine) - Bristol-Myers Squibb - Gliadel Wafer (carmustine in polifeprosan) - Eisai - Lomustine - Carboplatin - Cyclophosphamide - Etoposide - Irinotecan 4 Glioblastoma Pipeline - DCVax-L - Northwest Biotherapeutics - Rindopepimut (CDX-110) - Celldex Therapeutics - Avastin (bevacizumab)- Roche - ICT-107 - ImmunoCellular Therapeutics - Cotara- Peregrine Pharmaceuticals - Eir-060- EirGen Pharma - Heat Map of Safety and Efficacy and Competitor Matrix for Glioblastoma Multiforme Pipeline 5 Market forecasts 6 Deals and Strategic Consolidations - Del Mar Pharmaceuticals Enters into Agreement with Guangxi Wuzhou Pharmaceutical - Immatics Biotechnologies Enters into Agreement with Cancer Research UK - ImmunoCellular Therapeutics Enters into Agreement with University of Pennsylvania - Bexion Pharmaceuticals Enters into Agreement with Cincinnati Children's Hospital Medical Center - Celldex Therapeutics Enters into Agreement with Duke University Brain Tumor Cancer Center 7 Appendix For more information visit http://www.researchandmarkets.com/research/4j...ioblastoma (full story)
Why Diamond Offshore Drilling Inc., Bristol-Meyers Squibb Company, and Allergan Inc. Are Today's 3 W
John Divine, The Motley Fool - Motley Fool - Wed Jun 04, 8:02PM CDT
It was a relatively unremarkable day on Wall Street today, a low-volume session that lacked astounding economic data or headline-making broad market swings. But beneath the stock market's calm surface, there was a healthy dose of chaos brewing -- a... (full story)
ASCO: Bristol-Myers Squibb and Merck Don't Disappoint
Brian Orelli, The Motley Fool - Motley Fool - Wed Jun 04, 6:38PM CDT
We knew going into American Society of Clinical Oncology annual meeting that immuno-oncology would be a big focus. And Bristol-Myers Squibb and Merck didn't disappoint. Rather than attacking the tumor directly, immuno-oncology drugs encourage... (full story)
Is Merck's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jun 04, 5:00PM CDT
Merck is one of the world's biggest drugmakers and is a staple in dividend investors' portfolios. That's because pharmaceutical companies such as Merck, Johnson & Johnson , and Bristol-Myers Squibb offer investors a steady (and... (full story)
